Compare ICU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICU | EDSA |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 12.8M |
| IPO Year | N/A | N/A |
| Metric | ICU | EDSA |
|---|---|---|
| Price | $0.26 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.5M | 37.8K |
| Earning Date | 11-13-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $881,000.00 | N/A |
| Revenue This Year | $691.85 | N/A |
| Revenue Next Year | $64.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1195.59 | N/A |
| 52 Week Low | $0.22 | $1.28 |
| 52 Week High | $3.07 | $4.49 |
| Indicator | ICU | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 36.22 |
| Support Level | $0.22 | $1.27 |
| Resistance Level | $0.28 | $1.50 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 25.29 | 27.27 |
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.